Widespread rumors that mRNA vaccines negatively impact fertility are unfounded, according to new research from the department of obstetrics and gynecology at Israel’s Sheba Medical Center.

The team studied 36 couples undergoing a second round of in-vitro fertilization (IVF) treatments. All had received both doses of the Pfizer COVID-19 vaccine between the two rounds. None of the couples showed any differences in parameters such as sperm quality, semen volume, ovarian stimulation or proportion of high-quality embryos compared to their IVF cycles prior to vaccination.

In fact, one-third of the couples conceived in the post-vaccination IVF round, whereas the usual success rate is about one-quarter.

The observational study, published in Reproductive Biology and Endocrinology, concluded that the “mRNA SARS-CoV-2 vaccine did not affect patients’ performance or ovarian reserve in their immediate subsequent IVF cycle.”

Lead author Dr. Raoul Orvieto, director of Sheba’s IVF Fertility Clinic, said they decided to do the study because many people fear the possible effects of the vaccines on fertility.

He noted that this is the first published study demonstrating that the vaccine has no effect on male or female fertility, but said that larger studies with longer follow-up will be needed to validate his team’s observations.

Orvieto also pointed out that some preliminary studies indicate COVID-19 illness may lead to decreased ovarian function or semen quality. His group in a previous study “could not demonstrate any effect of COVID-19 infection on the ovarian stimulation characteristics and embryological variables of patients’ IVF treatments, except for a reduced proportion of top-quality embryos.”

This article was first published by Israel21c.


Jewish News Syndicate

With geographic, political and social divides growing wider, high-quality reporting and informed analysis are more important than ever to keep people connected.

Our ability to cover the most important issues in Israel and throughout the Jewish world—without the standard media bias—depends on the support of committed readers.

If you appreciate the value of our news service and recognize how JNS stands out among the competition, please click on the link and make a one-time or monthly contribution.

We appreciate your support.